Japanese encephalitis: epidemiology, prevention and current status of antiviral drug development

Bibliography

• Pierson TC, Diamond MS. Flaviviruses. In: Knipe DM, Howley PM, editors. Fields virology. 6th edition. Lippincott William, Philadelphia; 2013. p. 747-94
   Google Scholar
• Ishikawa T, Yamanaka A, Konishi E. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine 2014;32:1326-37
   PubMed Web of Science ®Google Scholar
• Diagana M, Preux PM, Dumas M. Japanese encephalitis revisited. J Neurol Sci 2007;262:165-70
   Google Scholar
• Sucharit S, Surathin K, Shrestha SR. Vectors of Japanese encephalitis virus (JEV): species complexes of the vectors. Southeast Asian J Trop Med Public Health 1989;20:611-21
   PubMedGoogle Scholar
• Le Flohic G, Porphyre V, Barbazan P, Gonzalez JP. Review of climate, landscape, and viral genetics as drivers of the Japanese encephalitis virus ecology. PLoS Negl Trop Dis 2013;7:e2208
   PubMed Web of Science ®Google Scholar
• van den Hurk AF, Ritchie SA, Mackenzie JS. Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol 2009;54:17-35
   PubMed Web of Science ®Google Scholar
• Hamano M, Lim CK, Takagi H, et al. Detection of antibodies to Japanese encephalitis virus in the wild boars in Hiroshima prefecture, Japan. Epidemiol Infect 2007;135:974-7
   PubMed Web of Science ®Google Scholar
• Ohno Y, Sato H, Suzuki K, et al. Detection of antibodies against Japanese encephalitis virus in raccoons, raccoon dogs and wild boars in Japan. J Vet Med Sci 2009;71:1035-9
   PubMed Web of Science ®Google Scholar
• Solomon T, Dung NM, Kneen R, et al. Japanese encephalitis. J Neurol Neurosurg Psychiatry 2000;68:405-15
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Konishi E. Combating Japanese encephalitis: vero-cell derived inactivated vaccines and the situation in Japan. Future Virol 2010;5:785-99
   Web of Science ®Google Scholar
• Lindenbach BD, Murray C, Thiel HJ, et al. Flaviviridae. In: Knipe DM, Howley PM, editors. Fields virology. 6th edition. Lippincott William, Philadelphia; 2013. p. 712-46
   Google Scholar
• Zhang W, Chipman PR, Corver J, et al. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol 2003;10:907-12
   PubMedGoogle Scholar
• Stadler K, Allison SL, Schalich J, Heinz FX. Proteolytic activation of tick-borne encephalitis virus by furin. J Virol 1997;71:8475-81
   PubMed Web of Science ®Google Scholar
• Kuhn RJ, Zhang W, Rossmann MG, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002;108:717-25
   PubMed Web of Science ®Google Scholar
• Kimura-Kuroda J, Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol 1988;141:3606-10
   PubMed Web of Science ®Google Scholar
• Kiermayr S, Kofler RM, Mandl CW, et al. Isolation of capsid protein dimers from the tick-borne encephalitis flavivirus and in vitro assembly of capsid-like particles. J Virol 2004;78:8078-84
   PubMed Web of Science ®Google Scholar
• Mason PW. Maturation of Japanese encephalitis virus glycoproteins produced by infected mammalian and mosquito cells. Virology 1989;169:354-64
   PubMed Web of Science ®Google Scholar
• Jan LR, Yang CS, Trent DW, et al. Processing of Japanese encephalitis virus non-structural proteins: NS2B-NS3 complex and heterologous proteases. J Gen Virol 1995;76:573-80
   PubMed Web of Science ®Google Scholar
• Kuo MD, Chin C, Hsu SL, et al. Characterization of the NTPase activity of Japanese encephalitis virus NS3 protein. J Gen Virol 1996;77:2077-84
   PubMed Web of Science ®Google Scholar
• Utama A, Shimizu H, Morikawa S, et al. Identification and characterization of the RNA helicase activity of Japanese encephalitis virus NS3 protein. FEBS Lett 2000;465:74-8
   PubMed Web of Science ®Google Scholar
• Wang Q, Weng L, Tian X, et al. Effect of the methyltransferase domain of Japanese encephalitis virus NS5 on the polymerase activity. Biochim Biophys Acta 2012;1819:411-18
   PubMed Web of Science ®Google Scholar
• Yu F, Hasebe F, Inoue S, et al. Identification and characterization of RNA-dependent RNA polymerase activity in recombinant Japanese encephalitis virus NS5 protein. Arch Virol 2007;152:1859-69
   PubMed Web of Science ®Google Scholar
• Perera-Lecoin M, Meertens L, Carnec X, Amara A. Flavivirus entry receptors: an update. Viruses 2014;6:69-88
   Web of Science ®Google Scholar
• Nawa M, Takasaki T, Yamada K, et al. Interference in Japanese encephalitis virus infection of Vero cells by a cationic amphiphilic drug, chlorpromazine. J Gen Virol 2003;84:1737-41
   PubMed Web of Science ®Google Scholar
• Zhu YZ, Xu QQ, Wu DG, et al. Japanese encephalitis virus enters rat neuroblastoma cells via a pH-dependent, dynamin and caveola-mediated endocytosis pathway. J Virol 2012;86:13407-22
   PubMed Web of Science ®Google Scholar
• Allison SL, Schalich J, Stiasny K, et al. Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH. J Virol 1995;69:695-700
   PubMed Web of Science ®Google Scholar
• Villordo SM, Gamarnik AV. Genome cyclization as strategy for flavivirus RNA replication. Virus Res 2009;139:230-9
   PubMed Web of Science ®Google Scholar
• Kim SM, Jeong YS. Polypyrimidine tract-binding protein interacts with the 3’ stem-loop region of Japanese encephalitis virus negative-strand RNA. Virus Res 2006;115:131-40
   PubMed Web of Science ®Google Scholar
• Ta M, Vrati S. Mov34 protein from mouse brain interacts with the 3’ noncoding region of Japanese encephalitis virus. J Virol 2000;74:5108-15
   PubMed Web of Science ®Google Scholar
• Vashist S, Anantpadma M, Sharma H, Vrati S. La protein binds the predicted loop structures in the 3’ non-coding region of Japanese encephalitis virus genome: role in virus replication. J Gen Virol 2009;90:1343-52
   PubMed Web of Science ®Google Scholar
• Chien HL, Liao CL, Lin YL. FUSE binding protein 1 interacts with untranslated regions of Japanese encephalitis virus RNA and negatively regulates viral replication. J Virol 2011;85:4698-706
   PubMed Web of Science ®Google Scholar
• Yang SH, Liu ML, Tien CF, et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) interaction with 3’ ends of Japanese encephalitis virus RNA and colocalization with the viral NS5 protein. J Biomed Sci 2009;16:40
   PubMed Web of Science ®Google Scholar
• Katoh H, Mori Y, Kambara H, et al. Heterogeneous nuclear ribonucleoprotein A2 participates in the replication of Japanese encephalitis virus through an interaction with viral proteins and RNA. J Virol 2011;85:10976-88
   PubMed Web of Science ®Google Scholar
• Li C, Ge LL, Li PP, et al. The DEAD-box RNA helicase DDX5 acts as a positive regulator of Japanese encephalitis virus replication by binding to viral 3’ UTR. Antiviral Res 2013;100:487-99
   PubMed Web of Science ®Google Scholar
• Li C, Ge LL, Li PP, et al. Cellular DDX3 regulates Japanese encephalitis virus replication by interacting with viral un-translated regions. Virology 2014;449:70-81
   PubMed Web of Science ®Google Scholar
• Igarashi A, Tanaka M, Morita K, et al. Detection of west Nile and Japanese encephalitis viral genome sequences in cerebrospinal fluid from acute encephalitis cases in Karachi, Pakistan. Microbiol Immunol 1994;38:827-30
   PubMed Web of Science ®Google Scholar
• Sugamata M, Ahmed A, Miura T, et al. Seroepidemiological study of infection with West Nile virus in Karachi, Pakistan, in 1983 and 1985. J Med Virol 1988;26:243-7
   PubMed Web of Science ®Google Scholar
• Hanna JN, Ritchie SA, Phillips DA, et al. An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med J Aust. 1996;165-256.60
   Google Scholar
• Van Den Hurk AF, Montgomery BL, Northill JA, et al. Short report: the first isolation of Japanese encephalitis virus from mosquitoes collected from mainland Australia. Am J Trop Med Hyg 2006;75:21-5
   PubMed Web of Science ®Google Scholar
• Solomon T, Ni H, Beasley DW, et al. Origin and evolution of Japanese encephalitis virus in Southeast Asia. J Virol 2003;77:3091-8
   PubMed Web of Science ®Google Scholar
• Nitatpattana N, Dubot-Peres A, Gouilh MA, et al. Change in Japanese encephalitis virus distribution, Thailand. Emerg Infect Dis 2008;14:1762-5
   PubMed Web of Science ®Google Scholar
• Nga PT, del Carmen Parquet M, Cuong VD, et al. Shift in Japanese encephalitis virus (JEV) genotype circulating in northern Vietnam: implications for frequent introductions of JEV from Southeast Asia to East Asia. J Gen Virol 2004;85:1625-31
   PubMed Web of Science ®Google Scholar
• Kuwata R, Nga PT, Yen NT, et al. Surveillance of Japanese encephalitis virus infection in mosquitoes in Vietnam from 2006 to 2008. Am J Trop Med Hyg 2013;88:681-8
   PubMed Web of Science ®Google Scholar
• Wang HY, Takasaki T, Fu SH, et al. Molecular epidemiological analysis of Japanese encephalitis virus in China. J Gen Virol 2007;88:885-94
   PubMed Web of Science ®Google Scholar
• Zheng Y, Li M, Wang H, Liang G. Japanese encephalitis and Japanese encephalitis virus in mainland China. Rev Med Virol 2012;22:301-22
   PubMed Web of Science ®Google Scholar
• Chen SP. Molecular phylogenetic and evolutionary analysis of Japanese encephalitis virus in China. Epidemiol Infect 2012;140:1637-43
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Tabei Y, Hasegawa M, et al. Genotypic analysis of Japanese encephalitis virus strains isolated from swine in Tokyo, Japan. Jpn J Infect Dis 2005;58:259-61
   PubMed Web of Science ®Google Scholar
• Ma SP, Yoshida Y, Makino Y, et al. Short report: a major genotype of Japanese encephalitis virus currently circulating in Japan. Am J Trop Med Hyg 2003;69:151-4
   PubMed Web of Science ®Google Scholar
• Tang WF, Ogawa M, Eshita Y, et al. Molecular evolution of Japanese encephalitis virus isolates from swine in Oita, Japan during 1980 – 2009. Infect Genet Evol 2010;10:329-36
   PubMed Web of Science ®Google Scholar
• Chen YY, Fan YC, Tu WC, et al. Japanese encephalitis virus genotype replacement, Taiwan, 2009 – 2010. Emerg Infect Dis 2011;17:2354-6
   PubMed Web of Science ®Google Scholar
• Huang JH, Lin TH, Teng HJ, et al. Molecular epidemiology of Japanese encephalitis virus, Taiwan. Emerg Infect Dis 2010;16:876-8
   Web of Science ®Google Scholar
• Fulmali PV, Sapkal GN, Athawale S, et al. Introduction of Japanese encephalitis virus genotype I, India. Emerg Infect Dis 2011;17:319-21
   PubMed Web of Science ®Google Scholar
• Pyke AT, Williams DT, Nisbet DJ, et al. The appearance of a second genotype of Japanese encephalitis virus in the Australasian region. Am J Trop Med Hyg 2001;65:747-53
   PubMed Web of Science ®Google Scholar
• Van Den Hurk AF, Montgomery BL, Northill JA, et al. Short report: the first isolation of Japanese encephalitis virus from mosquitoes collected from mainland Australia. Am J Trop Med Hyg 2006;75:21-5
   PubMed Web of Science ®Google Scholar
• Li MH, Fu SH, Chen WX, et al. Genotype v Japanese encephalitis virus is emerging. PLoS Negl Trop Dis 2011;5:e1231
   PubMed Web of Science ®Google Scholar
• Takhampunya R, Kim HC, Tippayachai B, et al. Emergence of Japanese encephalitis virus genotype V in the Republic of Korea. Virol J 2011;8:449
   PubMed Web of Science ®Google Scholar
• Campbell GL, Hills SL, Fischer M, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 2011;89:766-74; 774A-774E
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Japanese encephalitis surveillance and immunization - Asia and the Western pacific, 2012. MMWR Morb Mortal Wkly Rep 2013;62:658-62
   PubMed Web of Science ®Google Scholar
• WHO. Japanese encephalitis reported cases. Available from: http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tsincidencejapenc.html; http://apps.who.int/immu
   Google Scholar
• Hills SL, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973 – 2008. Am J Trop Med Hyg 2010;82:930-6
   PubMed Web of Science ®Google Scholar
• Arai S, Matsunaga Y, Takasaki T, et al. Japanese encephalitis: surveillance and elimination effort in Japan from 1982 to 2004. Jpn J Infect Dis 2008;61:333-8
   PubMed Web of Science ®Google Scholar
• Wu YC, Huang YS, Chien LJ, et al. The epidemiology of Japanese encephalitis on Taiwan during 1966 – 1997. Am J Trop Med Hyg 1999;61:78-84
   PubMed Web of Science ®Google Scholar
• Kim HC, Turell MJ, O’Guinn ML, et al. Historical review and surveillance of Japanese encephalitis, Republic of Korea, 2002 – 2004. Entomol Res 2007;37:267-74
   Google Scholar
• Lee DW, Choe YJ, Kim JH, et al. Epidemiology of Japanese encephalitis in South Korea, 2007 – 2010. Int J Infect Dis 2012;16:e448-52
   PubMed Web of Science ®Google Scholar
• Muangchana C, Henprasertthae N, Nurach K, et al. Effectiveness of mouse brain-derived inactivated Japanese encephalitis vaccine in Thai National Immunization Program: a case-control study. Vaccine 2012;30:361-7
   PubMed Web of Science ®Google Scholar
• Ministry Of Health, Malaysia. Annual report 2002. Available from: http://www.moh.gov.my/images/gallery/publications/md/ar/2002-1.pdf; http://www.moh.gov.my/im
   Google Scholar
• Ministry of Health Malaysia. Annual report 2011. Available from: http://www.moh.gov.my/images/gallery/publications/md/ar/2011_en.pdf; http://www.moh.gov.my/im
   Google Scholar
• Kurane I, Takasaki T. Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains. Vaccine 2000;18(Suppl 2):33-5
   PubMed Web of Science ®Google Scholar
• Hsu TC, Chow LP, Wei HY, et al. A controlled field trial for an evaluation of effectiveness of mouse-brain Japanese encephalitis vaccine. Taiwan Yi Xue Hui Za Zhi 1971;70:55-62
   PubMedGoogle Scholar
• Hoke CH, Nisalak A, Sangawhipa N, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1988;319:608-14
   PubMed Web of Science ®Google Scholar
• Schioler KL, Samuel M, Wai KL. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst Rev 2007;18:CD004263
   Google Scholar
• Huynh W, Cordato DJ, Kehdi E, et al. Post-vaccination encephalomyelitis: literature review and illustrative case. J Clin Neurosci 2008;15:1315-22
   PubMed Web of Science ®Google Scholar
• Japanese Encephalitis Vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59:1-27
   PubMedGoogle Scholar
• Jelinek T. IXIARO((R)) updated: overview of clinical trials and developments with the inactivated vaccine against Japanese encephalitis. Expert Rev Vaccines 2013;12:859-69
   PubMed Web of Science ®Google Scholar
• Hombach J, Solomon T, Kurane I, et al. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2 – 3 September, 2004. Vaccine 2005;23:5205-11
   PubMed Web of Science ®Google Scholar
• Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007;370:1847-53
   PubMed Web of Science ®Google Scholar
• Schuller E, Jilma B, Voicu V, et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 2008;26:4382-6
   PubMed Web of Science ®Google Scholar
• Tauber E, Kollaritsch H, von Sonnenburg F, et al. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008;198:493-9
   PubMed Web of Science ®Google Scholar
• Schuller E, Klade CS, Wolfl G, et al. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 2009;27:2188-93
   PubMed Web of Science ®Google Scholar
• Kaltenbock A, Dubischar-Kastner K, Schuller E, et al. Immunogenicity and safety of IXIARO((R)) (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 2010;28:834-9
   PubMed Web of Science ®Google Scholar
• Kikukawa A, Gomi Y, Akechi M, et al. Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated). Vaccine 2012;30:2329-35
   PubMed Web of Science ®Google Scholar
• Okada K, Iwasa T, Namazue J, et al. Safety and immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (Inactivated) (JEBIK((R))V) in children. Vaccine 2012;30:5967-72
   PubMed Web of Science ®Google Scholar
• Miyazaki C, Okada K, Ozaki T, et al. Phase III clinical trials comparing the immunogenicity and safety of the vero cell-derived Japanese encephalitis vaccine encevac with those of mouse brain-derived vaccine by using the Beijing-1 strain. Clin Vaccine Immunol 2014;21:188-95
   Google Scholar
• Xin YY, Ming ZG, Peng GY, et al. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am J Trop Med Hyg 1988;39:214-17
   PubMed Web of Science ®Google Scholar
• Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 2000(18(Suppl 2):1-25
   PubMedGoogle Scholar
• Liu ZL, Hennessy S, Strom BL, et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J Infect Dis 1997;176:1366-9
   PubMed Web of Science ®Google Scholar
• Bista MB, Banerjee MK, Shin SH, et al. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 2001;358:791-5
   PubMed Web of Science ®Google Scholar
• Ohrr H, Tandan JB, Sohn YM, et al. Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet 2005;366:1375-8
   PubMed Web of Science ®Google Scholar
• Kumar R, Tripathi P, Rizvi A. Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N Engl J Med 2009;360:1465-6
   PubMed Web of Science ®Google Scholar
• Sohn YM, Tandan JB, Yoksan S, et al. A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses. Vaccine 2008;26:1638-43
   PubMed Web of Science ®Google Scholar
• Tandan JB, Ohrr H, Sohn YM, et al.Single dose of SA. 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 2007;25:5041-5
   PubMed Web of Science ®Google Scholar
• Liu Y, Lin H, Zhu Q, et al. Safety of Japanese encephalitis live attenuated vaccination in post-marketing surveillance in Guangdong, China, 2005 – 2012. Vaccine 2014;32:1768-73
   PubMed Web of Science ®Google Scholar
• Takahashi H, Pool V, Tsai1 TF, Chen RT. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group. Vaccine 2000;18:2963-9
   PubMed Web of Science ®Google Scholar
• Lindsey NP, Staples JE, Jones JF, et al. Adverse event reports following Japanese encephalitis vaccination in the United States, 1999 – 2009. Vaccine 2010;29:58-64
   PubMed Web of Science ®Google Scholar
• Guy B, Guirakhoo F, Barban V, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010;28:632-49
   PubMed Web of Science ®Google Scholar
• Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003;188:1213-30
   PubMed Web of Science ®Google Scholar
• Torresi J, McCarthy K, Feroldi E, Meric C. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled phase 3 trials. Vaccine 2010;28:7993-8000
   PubMed Web of Science ®Google Scholar
• Feroldi E, Pancharoen C, Kosalaraksa P, et al. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial. Hum Vaccin Immunother 2012;8:929-37
   PubMed Web of Science ®Google Scholar
• Nasveld PE, Ebringer A, Elmes N, et al. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults. Hum Vaccin 2010;6:1038-46
   PubMed Web of Science ®Google Scholar
• Global Advisory Committee on Vaccine Safety, 11-12 December 2013. Wkly Epidemiol Rec 2014;89:53-60
   PubMedGoogle Scholar
• Erra EO, Askling HH, Yoksan S, et al. Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes. Clin Infect Dis 2013;56:267-70
   PubMed Web of Science ®Google Scholar
• Liu X, Yu Y, Li M, et al. Study on the protective efficacy of SA14-14-2 attenuated Japanese encephalitis against different JE virus isolates circulating in China. Vaccine 2011;29:2127-30
   Google Scholar
• Beasley DW, Li L, Suderman MT, et al. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine 2004;22:3722-6
   PubMed Web of Science ®Google Scholar
• Harinasuta C, Wasi C, Vithanomsat S. The effect of interferon on Japanese encephalitis virus in vitro. Southeast Asian J Trop Med Public Health 1984;15:564-8
   PubMedGoogle Scholar
• Solomon T, Dung NM, Wills B, et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet 2003;361:821-6
   PubMed Web of Science ®Google Scholar
• Crance JM, Scaramozzino N, Jouan A, Garin D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res 2003;58:73-9
   PubMed Web of Science ®Google Scholar
• Kumar R, Tripathi P, Baranwal M, et al. Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India. Clin Infect Dis 2009;48:400-6
   PubMed Web of Science ®Google Scholar
• Shi Z, Wei J, Deng X, et al. Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model. Virol J 2014;11:10
   PubMed Web of Science ®Google Scholar
• Ishag HZ, Li C, Huang L, et al. Griffithsin inhibits Japanese encephalitis virus infection in vitro and in vivo. Arch Virol 2013;158:349-58
   PubMed Web of Science ®Google Scholar
• Chang SJ, Chang YC, Lu KZ, et al. Antiviral activity of isatis indigotica extract and its derived indirubin against Japanese encephalitis virus. Evid Based Complement Alternat Med 2012;2012:925830
   PubMed Web of Science ®Google Scholar
• Ishag HZ, Li C, Huang L, et al. Inhibition of Japanese encephalitis virus infection in vitro and in vivo by pokeweed antiviral protein. Virus Res 2013;171:89-96
   PubMed Web of Science ®Google Scholar
• Sebastian L, Desai A, Yogeeswari P, et al. Combination of N-methylisatin-beta-thiosemicarbazone derivative (SCH16) with ribavirin and mycophenolic acid potentiates the antiviral activity of SCH16 against Japanese encephalitis virus in vitro. Lett Appl Microbiol 2012;55:234-9
   PubMed Web of Science ®Google Scholar
• Murakami M, Ota T, Nukuzuma S, Takegami T. Inhibitory effect of RNAi on Japanese encephalitis virus replication in vitro and in vivo. Microbiol Immunol 2005;49:1047-56
   PubMed Web of Science ®Google Scholar
• Kumar P, Lee SK, Shankar P, Manjunath N. A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med 2006;3:e96
   PubMed Web of Science ®Google Scholar
• Anantpadma M, Vrati S. siRNA-mediated suppression of Japanese encephalitis virus replication in cultured cells and mice. J Antimicrob Chemother 2012;67:444-51
   PubMed Web of Science ®Google Scholar
• Nazmi A, Dutta K, Basu A. Antiviral and neuroprotective role of octaguanidinium dendrimer-conjugated morpholino oligomers in Japanese encephalitis. PLoS Negl Trop Dis 2010;4:e892
   PubMed Web of Science ®Google Scholar
• Anantpadma M, Stein DA, Vrati S. Inhibition of Japanese encephalitis virus replication in cultured cells and mice by a peptide-conjugated morpholino oligomer. J Antimicrob Chemother 2010;65:953-61
   PubMed Web of Science ®Google Scholar
• Wu Z, Xue Y, Wang B, et al. Broad-spectrum antiviral activity of RNA interference against four genotypes of Japanese encephalitis virus based on single microRNA polycistrons. PLoS One 2011;6:e26304
   PubMed Web of Science ®Google Scholar
• Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007;448:39-43
   PubMed Web of Science ®Google Scholar
• Subramanya S, Kim SS, Abraham S, et al. Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. J Virol 2010;84:2490-501
   PubMed Web of Science ®Google Scholar
• Chen J, Yamada S, Hama Y, et al. Unique heparan sulfate from shrimp heads exhibits a strong inhibitory effect on infections by dengue virus and Japanese encephalitis virus. Biochem Biophys Res Commun 2011;412:136-42
   PubMed Web of Science ®Google Scholar
• Zu X, Liu Y, Wang S, et al. Peptide inhibitor of Japanese encephalitis virus infection targeting envelope protein domain III. Antiviral Res 2014;104C:7-14
   Web of Science ®Google Scholar
• Li C, Ge LL, Yu YL, et al. A tripeptide (NSK) inhibits Japanese encephalitis virus infection in vitro and in vivo. Arch Virol. Available from: http://dx.doi.org/10.1007/s00705-013-1925-y
   Google Scholar
• Luca VC, AbiMansour J, Nelson CA, Fremont DH. Crystal structure of the Japanese encephalitis virus envelope protein. J Virol 2012;86:2337-46
   PubMed Web of Science ®Google Scholar
• Lu G, Gong P. Crystal Structure of the full-length Japanese encephalitis virus NS5 reveals a conserved methyltransferase-polymerase interface. PLoS Pathog 2013;9:e1003549
   PubMed Web of Science ®Google Scholar
• Yamashita T, Unno H, Mori Y, et al. Crystal structure of the catalytic domain of Japanese encephalitis virus NS3 helicase/nucleoside triphosphatase at a resolution of 1.8 A. Virology 2008;373:426-36
   PubMed Web of Science ®Google Scholar
• Kaczor A, Matosiuk D. Structure-based virtual screening for novel inhibitors of Japanese encephalitis virus NS3 helicase/nucleoside triphosphatase. FEMS Immunol Med Microbiol 2010;58:91-101
   PubMed Web of Science ®Google Scholar
• Agnihotri S, Narula R, Joshi K, et al. In silico modeling of ligand molecule for non structural 3 (NS3) protein target of flaviviruses. Bioinformation 2012;8:123-7
   PubMedGoogle Scholar
• GAVI alliance. Available from: http://www.gavialliance.org/support/nvs/japanese-encephalitis/;http://www.gavialliance
   Google Scholar
• Bariya SH, Gohel MC, Mehta TA, Sharma OP. Microneedles: an emerging transdermal drug delivery system. J Pharm Pharmacol 2012;64:11-29
   PubMed Web of Science ®Google Scholar
• Puig-Basagoiti F, Deas TS, Ren P, et al. High-throughput assays using a luciferase-expressing replicon, virus-like particles, and full-length virus for West Nile virus drug discovery. Antimicrob Agents Chemother 2005;49:4980-8
   PubMed Web of Science ®Google Scholar